Zimbabwe has rejected a substantial American health deal worth $367m (£272m) over five years because of Washington's request for confidential biological samples.
The decision became public following a internal memorandum from December was leaked, which showed Head of State Emmerson Mnangagwa deemed the agreement was "unbalanced".
A government spokesman later explained that the United States was seeking genetic material for research and commercial purposes but was not willing to share the benefits from future vaccines.
"We are forced to start the challenging and unfortunate process of scaling back our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had furnished more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged more dialogue to reach a agreement agreeable to both sides so the country's critical HIV programme can continue.
Wider Implications
This development comes after a similar case in Kenya, where a high court suspended a similar deal with the US after concerns were raised about the safety of Kenyans' health data.
After resuming the presidency recently, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump claimed its spending was "wasteful" and his government was pursuing government-to-government deals to boost transparency and accountability.
According to reports, Sixteen nations in Africa have to date signed these new health pacts, representing over $18.3bn in new funding.
Specifics of the Declined Deal
This assistance for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration could have provided extraordinary advantages for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving HIV treatment through American-funded programmes," Tremont said.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"Our nation was requested to surrender its genetic material and health information for a long time, with no corresponding assurance of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," his statement read.
"In essence, our nation would provide the raw materials for medical research with no certainty that the end products would be accessible to our citizens should a new pandemic arise."
Sovereignty and Global Health
He also said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were upending systems previously set up via the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework created to manage future pandemics.
"This system is intended to guarantee that when a nation contributes its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the capability to create them."
The government's concerns over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome continued discussions with our US partners on how future collaboration might be arranged in a manner that respects the independence and interests of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the official position, but urged that negotiations should continue considering much of the country's HIV programmes were funded by international support.
"Where specific concerns exist, such as those involving data governance or agreement terms, these can frequently be resolved via technical clarification and mutually agreed protections," it said.
The situation highlights the continuing debate between accepting vital international aid and protecting local interests in an increasingly data-driven world.